Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT
INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") to provide its shareholders and potential investors with information in relation to the latest development of the Company.

The board (the "**Board**") of directors of the Company is pleased to announce that, in accordance with relevant provisions of the *Implementing Measures of the Shanghai Stock Exchange for the Shanghai-Hong Kong Stock Connect (《上海證券交易所滬港通業務實施辦法》)* and the *Implementing Measures of the Shenzhen Stock Exchange for the Shenzhen-Hong Kong Stock Connect (《深圳證券交易所深港通業務實施辦法》)*, the shares (the "**H Shares**") issued and listed by the Company on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") are in included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs (collectively referred to as the "**Stock Connect**") with effect from December 24, 2025.

Following the inclusion of the H Shares of the Company in the list of eligible securities under the Stock Connect, eligible investors in the mainland China will be able to directly invest in the H Shares of the Company listed on the Hong Kong Stock Exchange via the Shanghai Stock Exchange and the Shenzhen Stock Exchange, which is conducive to further expand the Company's investor base and potentially enhance the trading liquidity of the H Shares of the Company.

About the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are mutual stock market access mechanisms between Mainland China and the Hong Kong Special Administrative Region, under which the Shanghai Stock Exchange and the Shenzhen Stock Exchange have established technical connectivity with the Hong Kong Stock Exchange, respectively, to enable investors in Mainland China and the Hong Kong Special Administrative Region to trade eligible shares listed on each other's market through their local securities companies or brokers.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, December 24, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian as executive director; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors; and Ms. Li Yan as employee director.